🔎 Trials Near Me

Home › Leukemia › Virginia

Leukemia clinical trials in Virginia

7 studies for Leukemia are looking for participants at sites in Virginia.

Cities in Virginia

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  • Quetzal Site 3, Charlottesville
RecruitingPhase 3
Ages 18 to 71 · All sexes · Updated Sep 23, 2026 · NCT07504458

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • University of Virginia Comprehensive Cancer Center, Charlottesville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Virginia School of Medicine, Charlottesville
  • Virginia Cancer Specialists, Manassas
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  • Research Site, Richmond
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Aug 19, 2026 · NCT06137118

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site, Charlottesville
  • Dren Investigational Site, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05475925

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Virginia Commonwealth University/Massey Cancer Center, Richmond
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Charlottesville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.